secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001493152-24-029174
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial
--------------------------------------------------------------------------------

- $8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.
- NEXICART-2 U.S. Phase 1b/2 trial to evaluate NXC-201; builds on prior ex-U.S. data showing 92% overall response rate.
- NXC-201 is the only CAR-T therapy in development for AL Amyloidosis and has Orphan Drug Designation from FDA and EMA.
- No FDA approved drugs currently for relapsed/refractory AL Amyloidosis; CIRM grant adds non-dilutive funding to ongoing clinical program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224029174/0001493152-24-029174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224029174/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-029174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer